HIV/AIDS and lipodystrophy: Implications for clinical management in resource-limited settings

Journal of the International AIDS Society

Volumn 18, Issue 1, 2015, Pages

  Finkelstein, Julia L ^a,b   Gala, Pooja ^c   Rochford, Rosemary ^d   Glesby, Marshall J ^e   Mehta, Saurabh ^a,b  

^a Department of Obstetrics Gynecology   (United States)

^b ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d State University of New York Upstate Medical University: College of Medicine   (United States)

^e NONE

Author keywords

AIDS; Antiretroviral therapy; Fat redistribution; HIV; Lipodystrophy

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; STAVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTHROPOMETRY; BODY COMPOSITION; DEVELOPING COUNTRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFESTYLE MODIFICATION; LIPOATROPHY; LIPOHYPERTROPHY; LONG TERM CARE; LOWEST INCOME GROUP; MEDICAL SUBJECT HEADINGS; MEDICATION COMPLIANCE; PREGNANT WOMAN; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RESOURCE MANAGEMENT; REVIEW; RISK FACTOR; SEX DIFFERENCE; ACQUIRED IMMUNODEFICIENCY SYNDROME; CHEMICALLY INDUCED; FEMALE; HEALTH CARE PLANNING; HIV INFECTIONS; LIPODYSTROPHY; MALE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; FEMALE; HEALTH RESOURCES; HIV INFECTIONS; HUMANS; LIPODYSTROPHY; MALE;

EID: 84921329867     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.18.1.19033     Document Type: Review

References (192)

1. Delaney M. History of HAART - the true story of how effective multi-drug therapy was developed for treatment of HIV disease. Retrovirology. 2006; 3(Suppl 1):S6.
2. Carr A. Lactic acidemia in infection with human immunodeficiency virus. Clin Infect Dis. 2003;36(Suppl 2):S96-100.
3. Calmy A, Hirschel B, Cooper DA, Carr A. Clinical update: adverse effects of antiretroviral therapy. Lancet. 2007;370(9581):12-4.
4. Dube NM, Summers R, Tint KS, Mayayise G. A pharmacovigilance study of adults on highly active antiretroviral therapy. South Africa: 2007-2011. Pan Afr Med J. 2012;11:39.
5. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352(1):48-62.
6. Tanwani LK, Mokshagundam SL. Lipodystrophy, insulin resistance, diabetes mellitus, dyslipidemia, and cardiovascular disease in human immunodeficiency virus infection. South Med J. 2003;96(2):180-8;quiz 189.
7. Duran S, Savès M, Spire B, Cailleton V, Sobel A, Carrieri P, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001;15(18):2441-4.
8. Mutimura E, Stewart A, Crowther NJ. Assessment of quality of life in HAART-treated HIV-positive subjects with body fat redistribution in Rwanda. AIDS Res Ther. 2007;4:19.
9. Plankey M, Bacchetti P, Jin C, Grimes B, Hyman C, Cohen M, et al. Self-perception of body fat changes and HAART adherence in the Women's Interagency HIV Study. AIDS Behav. 2009;13(1):53-9.
10. Baril JG, Junod P, Leblanc R, Dion H, Therrien R, Laplante F, et al. HIV-associated lipodystrophy syndrome: a review of clinical aspects. Can J Infect Dis Med Microbiol. 2005;16(4):233-43.
11. van Griensven J, De Naeyer L, Mushi T, Ubarijoro S, Gashumba D, Gazille C, et al. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans Roy Soc Trop Med Hyg. 2007;101(8):793-8.
12. Mercier S, Gueye NF, Cournil A, Fontbonne A, Copin N, Ndiaye I, et al. Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study. J Acquir Immune Defic Syndr. 2009;51(2):224-30.
13. Phillips DR, Hay P. Current perspectives on the management and prevention of antiretroviral-associated lipoatrophy. J Antimicrob Chemother. 2008;62(5):866-71.
14. Lichtenstein KA. Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr. 2005;39(4):395-400.
15. Bacchetti P, Gripshover B, Grunfeld C, Heymsfield S, McCreath H, Osmond D, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr. 2005;40(2):121-31.
16. Jouquet G, Bygrave H, Kranzer K, Ford N, Gadot L, Lee J, et al. Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho. J Acquir Immune Defic Syndr. 2011;58(3):e68-74.
17. Smit E, Skolasky RL, Dobs AS, Calhoun BC, Visscher BR, Palella FJ, et al. Changes in the incidence and predictors of wasting syndrome related to human immunodeficiency virus infection, 1987-1999. Am J Epidemiol. 2002;156(3):211-8.
18. Kolčić I. Double burden of malnutrition: a silent driver of double burden of disease in low- and middle-income countries. J Glob Health. 2012;2(2):20303.
19. de Waal R, Cohen K, Maartens G. Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. PLoS One. 2013;8(5):e63623.
20. W.B. Group, editor. Country and lending groups. In: World development indicators, Washington, DC, USA: W.B. Group; 2012. p. xxiii
21. Thiébaut R, Daucourt V, Mercié P, Ekouévi DK, Malvy D, Morlat P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidémiologie Clinique du Syndrome d'Immunodéficience Acquise en Aquitaine. Clin Infect Dis. 2000;31(6):1482-7.
22. Nguyen A, Calmy A, Schiffer V, Bernasconi E, Battegay M, Opravil M, et al. Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006. HIV Med. 2008;9(3):142-50.
23. Chen D, Misra A, Garg A. Clinical review 153: lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab. 2002; 87(11):4845-56.
24. Dai Y, Qiu ZF, Li TS, Han Y, Zuo LY, Xie J, et al. Clinical outcomes and immune reconstitution in 103 advanced AIDS patients undergoing 12-month highly active antiretroviral therapy. Chin Med J (Engl). 2006;119(20):1677-82.
25. Zhou HY, Zheng YH, He Y, Chen Z, Liu M, Yin W, et al. Evaluation of a 6-year highly active antiretroviral therapy in Chinese HIV-1-infected patients. Intervirology. 2010;53(4):240-6.
26. Luo L, Zhang L, Tao M, Qiu Z, Xie J, Han Y, et al. Adiponectin and leptin levels in Chinese patients with HIV-related lipodystrophy: a 30-month prospective study. AIDS Res Hum Retroviruses. 2009;25(12):1265-72.
27. Likanonsakul S, Rattanatham T, Feangvad S, Uttayamakul S, Prasithsirikul W, Srisopha S, et al. Polymorphisms in fas gene is associated with HIV-related lipoatrophy in Thai patients. AIDS Res Hum Retroviruses. 2012;29(1):142-50.
28. Desakorn V, Karmacharya BM, Thanachartwet V, Kyaw NL, Tansuphaswadikul S, Sahassananda D, et al. Effectiveness of fixed-dose combination stavudine, lamivudine and nevirapine (GPO-VIR) for treatment of naïve HIV patients in Thailand: a 3-year follow-up. Southeast Asian J Trop Med Public Health. 2011; 42(6):1414-22.
29. Tin EE, Bowonwatanuwong C, Desakorn V, Wilairatana P, Krudsood S, Pitisuttithum P, et al. The efficacy and adverse effects of GPO-VIR (stavudine+ lamivudine+nevirapine) in treatment-naïve adult HIV patients. Southeast Asian J Trop Med Public Health. 2005;36(2):362-9.
30. Kumarasamy N, Venkatesh KK, Devaleenal B, Poongulali S, Yepthomi T, Solomon S, et al. Safety, tolerability, and efficacy of second-line generic protease inhibitor containing HAART after first-line failure among South Indian HIV-infected patients. J Int Assoc Physicians AIDS Care (Chic). 2011; 10(2):71-5.
31. Padmapriyadarsini C, Swaminathan S, Karthipriya MJ, Narendran G, Menon PA, Thomas BE, et al. Morphologic and body composition changes are different in men and women on generic combination antiretroviral therapy - an observational study. J Assoc Physicians India. 2010;58:375-7.
32. Phan V, Thai S, Choun K, Lynen L, van Griensven J. Incidence of treatment-limiting toxicity with stavudine-based antiretroviral therapy in Cambodia: a retrospective cohort study. PLoS One. 2012;7(1):e30647.
33. Zannou DM, Denoeud L, Lacombe K, Amoussou-Guenou D, Bashi J, Akakpo J, et al. Incidence of lipodystrophy and metabolic disorders in patients starting non-nucleoside reverse transcriptase inhibitors in Benin. Antivir Ther. 2009;14(3):371-80.
34. Mutimura E, Stewart A, Rheeder P, Crowther NJ. Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;46(4):451-5.
35. Hurley E, Coutsoudis A, Giddy J, Knight SE, Loots E, Esterhuizen TM, et al. Weight evolution and perceptions of adults living with HIV following initiation of antiretroviral therapy in a South African urban setting. S Afr Med J. 2011;101(9):645-50.
36. Cournil A, Coudray M, Kouanfack C, Essomba CN, Tonfack CA, Biwolé-Sida M, et al. Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon. Antivir Ther. 2010;15(7):1039-43.
37. Gelenske T, e Farias FA, de Alencar Ximenes RA, de Melo HR, de Albuquerque MeF, de Carvalho EH, et al. Risk factors in human immunodeficiency virus/acquired immunodeficiency syndrome patients undergoing antiretroviral therapy in the state of Pernambuco, Brazil: a case-control study. Metab Syndr Relat Disord. 2010;8(3):271-7.
38. Trinca JR, Sprinz E, Lazzaretti RK, Hutz MH, Kuhmmer R, de Almeida S, et al. SNPs in the APM1 gene promoter are associated with adiponectin levels in HIV-infected individuals receiving HAART. J Acquir Immune Defic Syndr. 2010; 55(3):299-305.
39. Diehl LA, Dias JR, Paes AC, Thomazini MC, Garcia LR, Cinagawa E, et al. Prevalence of HIV-associated lipodystrophy in Brazilian outpatients: relation with metabolic syndrome and cardiovascular risk factors. Arq Bras Endocrinol Metabol. 2008;52(4):658-67.
40. Segatto AF, Freitas Junior IF, Santos VR, Alves KC, Barbosa DA, Portelinha Filho AM, et al. Lipodystrophy in HIV/AIDS patients with different levels of physical activity while on antiretroviral therapy. Rev Soc Bras Med Trop. 2011;44(4):420-4.
41. Wilson G, Wolff M. A decade of antiretroviral therapy: a profile of patients with 10 years of highly effective triple therapy. Rev Chilena Infectol. 2012; 29(3):337-43.
42. Menezes CN, Maskew M, Sanne I, Crowther NJ, Raal FJ. A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infect Dis. 2011;11:244.
43. van Griensven J, Zachariah R, Rasschaert F, Mugabo J, Atté EF, Reid T, et al. Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda. Trans R Soc Trop Med Hyg. 2010;104(2):148-53.
44. Pujades-Rodríguez M, Schramm B, Som L, Nerrienet E, Narom P, Chanchhaya N, et al. Immunovirological outcomes and resistance patterns at 4 years of antiretroviral therapy use in HIV-infected patients in Cambodia. Trop Med Int Health. 2011;16(2):205-13.
45. Brown TT. Approach to the human immunodeficiency virus-infected patient with lipodystrophy. J Clin Endocrinol Metab. 2008;93(8):2937-45.
46. Grunfeld C, Saag M, Cofrancesco J Jr., Lewis CE, Kronmal R, Heymsfield S, et al. Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy. AIDS. 2010;24(11):1717-26.
47. McComsey GA, Kitch D, Sax PE, Tebas P, Tierney C, Jahed NC, et al. Peripheral and central fat changes in subjects randomized to abacavirlamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis. 2011;53(2):185-96.
48. Boulle A, Orrel C, Kaplan R, Van Cutsem G, McNally M, Hilderbrand K, et al. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther. 2007;12(5):753-60.
49. George JA, Venter WD, Van Deventer HE, Crowther NJ. A longitudinal study of the changes in body fat and metabolic parameters in a South African population of HIV-positive patients receiving an antiretroviral therapeutic regimen containing stavudine. AIDS Res Hum Retroviruses. 2009;25(8):771-81.
50. Chuapai Y, Kiertiburanakul S, Malathum K, Sungkanuparph S. Lipodystrophy and dyslipidemia in human immunodeficiency virus-infected Thai patients receiving antiretroviral therapy. J Med Assoc Thai. 2007;90(3):452-8.
51. Kalyanasundaram AP, Jacob SM, Hemalatha R, Sivakumar MR. Prevalence of lipodystrophy and dyslipidemia among patients with HIV infection on generic ART in rural South India. J Int Assoc Physicians AIDS Care (Chic). 2012;11(5):329-34.
52. Andany N, Raboud JM, Walmsley S, Diong C, Rourke SB, Rueda S, et al. Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada. HIV Clin Trials. 2011;12(2):89-103.
53. Guaraldi G, Baraboutis IG. Evolving perspectives on HIV-associated lipodystrophy syndrome: moving from lipodystrophy to non-infectious HIV co-morbidities. J Antimicrob Chemother. 2009;64(3):437-40.
54. Carvalho Costa IM, Salaro CP, Costa MC. Polymethylmethacrylate facial implant: a successful personal experience in Brazil for more than 9 years. Dermatol Surg. 2009;35(8):1221-7.
55. Orsi AT, Miranda AE, Souza AC, Silva LC, Dias GR, Talhari C, et al. Lipoatrophy in patients with AIDS: treatment with polymethylmethacrylate in Amazonas, Brazil. Int J Dermatol. 2011;50(10):1255-8.
56. Serra MS, Oyafuso LK, Trope BM, Munhoz Leite OH, Ramos-E-Silva M. An index for staging facial lipoatrophy and evaluation of the efficacy of the treatment with polymethylmethacrylate in HIV/AIDS patients: a pilot study. J Eur Acad Dermatol Venereol. 2012;27(8):990-6.
57. Soares FM, Costa IM. HIV-associated facial lipoatrophy: from the advent to current knowledge. An Bras Dermatol. 2011;86(5):843-62;quiz 863-4.
58. Soares FM, Costa IM. Treatment of HIV-associated facial lipoatrophy: impact on infection progression assessed by viral load and CD4 count. An Bras Dermatol. 2013;88(4):570-7.
59. Warde M, Gragnani A, Gomes H, Hochman B, Ferreira LM. The impact of facial lipoatrophy treatment with polymethyl methacrylate in AIDS patients as measured by four quality-of-life questionnaires. Int J STD AIDS. 2011; 22(10):596-9.
60. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG, et al. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet. 2003;361(9359):726-35.
61. Asha HS, Seshadri MS, Paul TV, Abraham OC, Rupali P, Thomas N. Human immunodeficiency virus-associated lipodystrophy: an objective definition based on dual-energy x-ray absorptiometry-derived regional fat ratios in a South Asian population. Endocr Pract. 2012;18(2):158-69.
62. Homsanit M, Nelson KE, Sonjai A, Anekthananon T, Suwanagool S, Cofrancesco J. Body shape and metabolic abnormalities in Thai HIV-infected patients. AIDS Res Hum Retroviruses. 2007;23(11):1314-21.
63. Scherzer R, Shen W, Bacchetti P, Kotler D, Lewis CE, Shlipak MG, et al. Simple anthropometric measures correlate with metabolic risk indicators as strongly as magnetic resonance imaging-measured adipose tissue depots in both HIV-infected and control subjects. Am J Clin Nutr. 2008;87(6):1809-17.
64. Sicotte M, Ledoux M, Zunzunegui MV, Ag Aboubacrine S, Nguyen VK, group A. Reliability of anthropometric measures in a longitudinal cohort of patients initiating ART in West Africa. BMC Med Res Methodol. 2010; 10:102.
65. Durnin JV, Rahaman MM. The assessment of the amount of fat in the human body from measurements of skinfold thickness. 1967. Br J Nutr. 2003;89(1):147-55.
66. Zillikens MC, Conway JM. Anthropometry in blacks: applicability of generalized skinfold equations and differences in fat patterning between blacks and whites. Am J Clin Nutr. 1990;52(1):45-51.
67. Moreno S, Miralles C, Negredo E, Domingo P, Estrada V, Gutiérrez F, et al. Disorders of body fat distribution in HIV-1-infected patients. AIDS Rev. 2009; 11(3):126-34.
68. Tien PC, Grunfeld C. What is HIV-associated lipodystrophy? Defining fat distribution changes in HIV infection. Curr Opin Infect Dis. 2004;17(1):27-32.
69. Monnerat BZ, Cerutti Junior C, Canic¸ali SC, Motta TR. Clinical and biochemical evaluation of HIV-related lipodystrophy in an ambulatory population from the Hospital Universitário Cassiano Antonio de Morais, Vitória, ES, Brazil. Braz J Infect Dis. 2008;12(4):364-8.
70. Siqueira Vassimon H, Jordao AA, Albuquerque de Paula FJ, Artioli Machado A, Pontes Monteiro J. Comparison of bioelectrical impedance with skinfold thickness and X-ray absorptiometry to measure body composition in HIV-infected with lipodistrophy. Nutr Hosp. 2011;26(3):458-64.
71. Schwenk A. Methods of assessing body shape and composition in HIV-associated lipodystrophy. Curr Opin Infect Dis. 2002;15(1):9-16.
72. Carr A, Law M, H.L.C.D.S. Group. An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J Acquir Immune Defic Syndr. 2003;33(5):571-6.
73. Lichtenstein KA, Ward DJ, Moorman AC, Delaney KM, Young B, Palella FJ, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS. 2001;15(11):1389-98.
74. Belloso WH, Quirós RE, Ivalo SA, Perman MI, Galich AM, Stern LD, et al. Agreement analysis of variables involved in lipodystrophy syndrome definition in HIV-infected patients. J Acquir Immune Defic Syndr. 2003;32(1):104-11.
75. Kotler D,Wang J, Pierson R. Body composition studies in patients with the acquired immunodeficiency syndrome. Am J Clin Nutr. 1985;42(6):1255-65.
76. Kotler DP, Tierney AR, Wang J, Pierson RN, Jr. Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr. 1989;50(3):444-7.
77. Swanson B, Keithley JK. Bioelectrical impedance analysis (BIA) in HIV infection: principles and clinical applications. J Assoc Nurses AIDS Care. 1998;9(1):49-54.
78. Falutz J. Therapy insight: body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy. Nat Clin Pract Endocrinol Metab. 2007;3(9):651-61.
79. Arpadi SM, Bethel J, Horlick M, Sarr M, Bamji M, Abrams EJ, et al. Longitudinal changes in regional fat content in HIV-infected children and adolescents. AIDS. 2009;23(12):1501-9.
80. Silver HJ, Welch EB, Avison MJ, Niswender KD. Imaging body composition in obesity and weight loss: challenges and opportunities. Diabetes Metab Syndr Obes. 2010;3:337-47.
81. Carey D, Wand H, Martin A, Rothwell S, Emery S, Cooper DA, et al. Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial. AIDS. 2005;19(12):1325-7.
82. Signorini DJ, Netto AM, Gabbay S, Monteiro MC, Signorini DH, Andrade MeF, et al. A comparison of sonographic assessments and clinical questionnaire in the diagnosis of HIV-associated lipodystrophy. J Int Assoc Physicians AIDS Care (Chic). 2011;10(6):351-6.
83. Aghdassi E, Arendt B, Salit IE, Allard JP. Estimation of body fat mass using dual-energy x-ray absorptiometry, bioelectric impedance analysis, and anthropometry in HIV-positive male subjects receiving highly active antiretroviral therapy. J Parenter Enteral Nutr. 2007;31(2):135-41.
84. Tungsiripat M, McComsey G. Pathogenesis and management of lipoatrophy. Curr HIV/AIDS Rep. 2008;5(2):55-63.
85. Leung VL, Glesby MJ. Pathogenesis and treatment of HIV lipohypertrophy. Curr Opin Infect Dis. 2011;24(1):43-9.
86. Caron-Debarle M, Lagathu C, Boccara F, Vigouroux C, Capeau J. HIV-associated lipodystrophy: from fat injury to premature aging. Trends Mol Med. 2010;16(5):218-29.
87. Giralt M, Domingo P, Guallar JP, Rodriguez de la Concepción ML, Alegre M, Domingo JC, et al. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV- 1/HAART-associated lipodystrophy. Antivir Ther. 2006;11(6):729-40.
88. Minami R, Yamamoto M, Takahama S, Ando H, Miyamura T, Suematsu E, et al. Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation: the minimal effect of raltegravir and atazanavir. J Infect Chemother. 2011;17(2):183-8.
89. Lagathu C, Bastard JP, Auclair M, Maachi M, Kornprobst M, Capeau J, et al. Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro. Antivir Ther. 2004;9(6):911-20.
90. Flint OP, Noor MA, Hruz PW, Hylemon PB, Yarasheski K, Kotler DP, et al. The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications. Toxicol Pathol. 2009;37(1): 65-77.
91. Mallewa JE, Wilkins E, Vilar J, Mallewa M, Doran D, Back D, et al. HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options. J Antimicrob Chemother. 2008;62(4):648-60.
92. Mallon PW. Pathogenesis of lipodystrophy and lipid abnormalities in patients taking antiretroviral therapy. AIDS Rev. 2007;9(1):3-15.
93. Pacenti M, Barzon L, Favaretto F, Fincati K, Romano S, Milan G, et al. Microarray analysis during adipogenesis identifies new genes altered by antiretroviral drugs. AIDS. 2006;20(13):1691-705.
94. Harp JB. New insights into inhibitors of adipogenesis. Curr Opin Lipidol. 2004;15(3):303-7.
95. Rosen ED, MacDougald OA. Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol. 2006;7(12):885-96.
96. Côté HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med. 2002;346(11):811-20.
97. Villarroya F, Domingo P, Giralt M. Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity. Trends Pharmacol Sci. 2005; 26(2):88-93.
98. Moyle G. Mechanisms of HIV and nucleoside reverse transcriptase inhibitor injury to mitochondria. Antivir Ther. 2005;10(Suppl 2):M47-52.
99. Ananworanich J, Nuesch R, Côté HC, Kerr SJ, Hill A, Jupimai T, et al. Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine - a Staccato trial substudy. J Antimicrob Chemother. 2008;61(6):1340-3.
100. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2002;46(3): 716-23.
101. Claas GJ, Jülg B, Goebel FD, Bogner J. Metabolic and anthropometric changes one year after switching from didanosine/stavudine to tenofovir in HIV-infected patients. Eur J Med Res. 2007;12(2):54-60.
102. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2):191-201.
103. van Griensven J, Lynen L, Colebunders R. Substituting tenofovir for stavudine in resource-limited settings: there are challenges ahead. AIDS. 2009;23(8):1027.
104. Brown TT, Chu H, Wang Z, Palella FJ, Kingsley L, Witt MD, et al. Longitudinal increases in waist circumference are associated with HIV-serostatus, independent of antiretroviral therapy. AIDS. 2007;21(13):1731-8.
105. Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS. 2003;17(7):971-9.
106. van Griensven J, Zachariah R, Mugabo J, Reid T. Weight loss after the first year of stavudine-containing antiretroviral therapy and its association with lipoatrophy, virological failure, adherence and CD4 counts at primary health care level in Kigali, Rwanda. Trans Roy Soc Trop Med Hyg. 2010;104(12):751-7.
107. Thompson V, Medard B, Taseera K, Chakera AJ, Andia I, Emenyonu N, et al. Regional anthropometry changes in antiretroviral-naïve persons initiating a Zidovudine-containing regimen in Mbarara, Uganda. AIDS Res Hum Retroviruses. 2011;27(7):785-91.
108. Mayer L, Walsh BT, Pierson RN, Heymsfield SB, Gallagher D, Wang J, et al. Body fat redistribution after weight gain in women with anorexia nervosa. Am J Clin Nutr. 2005;81(6):1286-91.
109. Martínez E. Disorders of fat partitioning in treated HIV-infection. Best Pract Res Clin Endocrinol Metab. 2011;25(3):415-27.
110. Nyblade L, Pande RP, Mathur S, MacQuarrie K, Kidd R, Banteyerga H, et al. Disentangling HIV and AIDS stigma in Ethiopia, Tanzania and Zambia. Washington, DC; International Center for Research on Women; 2003.
111. Palmer M, Chersich M, Moultrie H, Kuhn L, Fairlie L, Meyers T. Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in Soweto, South Africa. AIDS. 2013;27(5):781-5.
112. Pujades-Rodríguez M, Dantony E, Pinoges L, Ecochard R, Etard JF, Carrillo-Casas E, et al. Toxicity associated with stavudine dose reduction from 40 to 30 mg in first-line antiretroviral therapy. PLoS One. 2011;6(11):e28112.
113. WHO, UNAIDS, UNICEF. Global HIV/AIDS response: epidemic update and health sector progress towards Universal Access: Progress Report. Geneva: WHO, UNAIDS, UNICEF; 2011.
114. World Health Organization. Global Price Reporting Mechanism (GPRM):AIDS medicines and diagnostic service (AMDS). Geneva: World Health Organization; 2012.
115. Ford N, Calmy A. Improving first-line antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS. 2010;5(1):38-47.
116. Maskew M, Westreich D, Fox MP, Maotoe T, Sanne IM. Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South Africa. J Int AIDS Soc. 2012;15(1):13. 10.1186/1758-2652-15-13.
117. Wangsomboonsiri W, Mahasirimongkol S, Chantarangsu S, Kiertiburanakul S, Charoenyingwattana A, Komindr S, et al. Association between HLA-B∗4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimen. Clin Infect Dis. 2010;50(4):597-604.
118. Bogner JR, Vielhauer V, Beckmann RA, Michl G, Wille L, Salzberger B, et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr. 2001;27(3):237-44.
119. Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L, et al. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS. 2006;20(8):1163-9.
120. Autar RS, Boyd MA, Wit FW, Ruxrungthams K, Sankote J, Lange J, et al. Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen. Antivir Ther. 2007;12(8):1265-71.
121. Boyd MA, Carr A, Ruxrungtham K, Srasuebkul P, Bien D, Law M, et al. Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz. J Infect Dis. 2006;194(5):642-50.
122. Santos CP, Felipe YX, Braga PE, Ramos D, Lima RO, Segurado AC, et al. Self-perception of body changes in persons living with HIV/AIDS: prevalence and associated factors. AIDS. 2005;19(Suppl 4):S14-21.
123. Savè s M, Raffi F, Capeau J, Rozenbaum W, Ragnaud JM, Perronne C, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2002;34(10):1396-405.
124. Miller J, Carr A, Emery S, Law M, Mallal S, Baker D, et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med. 2003;4(3):293-301.
125. Gupta V, Biswas A, Sharma SK. Metabolic and body composition changes after six months of highly active antiretroviral therapy in northern Indian patients. Int J STD AIDS. 2011;22(1):46-9.
126. Haugaard SB, Andersen O, Halsall I, Iversen J, Hales CN, Madsbad S, et al. Impaired proinsulin secretion before and during oral glucose stimulation in HIV-infected patients who display fat redistribution. Metabolism. 2007; 56(7):939-46.
127. Grinspoon SK. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am J Med. 2005;118(Suppl 2):23S-8S.
128. Kosmiski LA, Kuritzkes DR, Lichtenstein KA, Glueck DH, Gourley PJ, Stamm ER, et al. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome. AIDS. 2001;15(15):1993-2000.
129. Meininger G, Hadigan C, Laposata M, Brown J, Rabe J, Louca J, et al. Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution. Metabolism. 2002;51(2):260-6.
130. Puttawong S, Prasithsirikul W, Vadcharavivad S. Prevalence of lipodystrophy in Thai-HIV infected patients. J Med Assoc Thai. 2004;87(6):605-11.
131. Ammassari A, Antinori A, Cozzi-Lepri A, Trotta MP, Nasti G, Ridolfo AL, et al. Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S140-4.
132. Nachega JB, Trotta MP, Nelson M, Ammassari A. Impact of metabolic complications on antiretroviral treatment adherence: clinical and public health implications. Curr HIV/AIDS Rep. 2009;6(3):121-9.
133. Mutimura E, Stewart A, Crowther NJ, Yarasheski KE, Cade WT. The effects of exercise training on quality of life in HAART-treated HIV-positive Rwandan subjects with body fat redistribution. Qual Life Res. 2008;17(3):377-85.
134. Shenoy A, Ramapuram JT, Unnikrishan B, Achappa B, Madi D, Rao S, et al. Effect of lipodystrophy on the quality of life among people living with HIV/AIDS (PLHIV) on highly active antiretroviral therapy. J Int Assoc Provid AIDS Care. 2013;13(5):471-5.
135. Mutimura E, Crowther NJ, Cade TW, Yarasheski KE, Stewart A. Exercise training reduces central adiposity and improves metabolic indices in HAART-treated HIV-positive subjects in Rwanda: a randomized controlled trial. AIDS Res Hum Retroviruses. 2008;24(1):15-23.
136. Florindo AA, de Oliveira Latorre MoR, Jaime PC, Segurado AA. Leisure time physical activity prevents accumulation of central fat in HIV/AIDS subjects on highly active antiretroviral therapy. Int J STD AIDS. 2007;18(10):692-6.
137. Terry L, Sprinz E, Stein R, Medeiros NB, Oliveira J, Ribeiro JP, et al. Exercise training in HIV-1-infected individuals with dyslipidemia and lipodystrophy. Med Sci Sports Exerc. 2006;38(3):411-7.
138. Fiorenza CG, Chou SH, Mantzoros CS. Lipodystrophy: pathophysiology and advances in treatment. Nat Rev Endocrinol. 2011;7(3):137-50.
139. Lindegaard B, Hansen T, Hvid T, van Hall G, Plomgaard P, Ditlevsen S, et al. The effect of strength and endurance training on insulin sensitivity and fat distribution in human immunodeficiency virus-infected patients with lipodystrophy. J Clin Endocrinol Metab. 2008;93(10):3860-9.
140. Almeida LB, Segurado AC, Duran AC, Jaime PC. Impact of a nutritional counseling program on prevention of HAART-related metabolic and morphologic abnormalities. AIDS Care. 2011;23(6):755-63.
141. Hill A, Ruxrungtham K, Hanvanich M, Katlama C, Wolf E, Soriano V, et al. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother. 2007;8(5):679-88.
142. Gerschenson M, Kim C, Berzins B, Taiwo B, Libutti DE, Choi J, et al. Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen. J Antimicrob Chemother. 2009;63(6):1244-50.
143. Boufassa F, Dulioust A, Lascaux AS, Meyer L, Boué F, Delfraissy JF, et al. Lipodystrophy in 685 HIV-1-treated patients: influence of antiretroviral treatment and immunovirological response. HIV Clin Trials. 2001;2(4):339-45.
144. van Griensven J, Zachariah R, Rasschaert F, Atté EF, Reid T. Weight evolution in HIV-1 infected women in Rwanda after stavudine substitution due to lipoatrophy: comparison of zidovudine with tenofovir/abacavir. Trans R Soc Trop Med Hyg. 2009;103(6):613-9.
145. Allavena C, Ferré V, Brunet-Franc¸ois C, Delfraissy JF, Lafeuillade A, Valantin MA, et al. Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2005;39(3):300-6.
146. Valantin MA, Lanoy E, Bentata M, Kalmykova O, Boutekadjirt A, Allavena C, et al. Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial. HIV Med. 2008;9(8):625-35.
147. Floridia M, Tamburrini E, Anzidei G, Tibaldi C, Guaraldi G, Guerra B, et al. Plasma lipid profile in pregnant women with HIV receiving nevirapine. AIDS Patient Care STDS. 2009;23(3):147-52.
148. Sturt AS, Dokubo EK, Sint TT. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women. Cochrane Database Syst Rev. 2010: CD008440.
149. Lain KY, Catalano PM. Metabolic changes in pregnancy. Clin Obstet Gynecol. 2007;50(4):938-48.
150. Barbaro G. Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk. Am J Ther. 2006;13(3): 248-60.
151. Barbaro G. Vascular injury, hypertension and coronary artery disease in human immunodeficiency virus infection. Clin Ter. 2008;159(1):51-5.
152. Berhane T, Yami A, Alemseged F, Yemane T, Hamza L, Kassim M, et al. Prevalence of lipodystrophy and metabolic syndrome among HIV positive individuals on highly active anti-retroviral treatment in Jimma, South West Ethiopia. Pan Afr Med J. 2012;13:43.
153. Dubé MP, Parker RA, Tebas P, Grinspoon SK, Zackin RA, Robbins GK, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS. 2005; 19(16):1807-18.
154. Feleke Y, Fekade D, Mezegebu Y. Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients. Ethiop Med J. 2012;50(3):221-30.
155. Jantarapakde J, Phanuphak N, Chaturawit C, Pengnonyang S, Mathajittiphan P, Takamtha P, et al. Prevalence of metabolic syndrome among antiretroviral-naive and antiretroviral-experienced HIV-1 infected Thai adults. AIDS Patient Care STDS. 2014;28(7):331-40.
156. Edgeworth A, Treacy MP, Hurst TP. Thiazolidinediones in the treatment of HIV/HAART-associated lipodystrophy syndrome. AIDS Rev. 2013;15(3): 171-80.
157. Raboud JM, Diong C, Carr A, Grinspoon S, Mulligan K, Sutinen J, et al. A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy. HIV Clin Trials. 2010;11(1):39-50.
158. Slama L, Lanoy E, Valantin MA, Bastard JP, Chermak A, Boutekatjirt A, et al. Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). Antivir Ther. 2008;13(1): 67-76.
159. Mutimura E, Anastos K, Zheng Lin, Cohen M, Binagwaho A, Kotler DP, et al. Effect of HIV infection on body composition and fat distribution in Rwandan women. J Int Assoc Physicians AIDS Care (Chic). 2010;9(3):173-8.
160. Bergman RN, Kim SP, Catalano KJ, Hsu IR, Chiu JD, Kabir M, et al. Why visceral fat is bad: mechanisms of the metabolic syndrome. Obesity. 2006; 14(Suppl 1):16S-9S.
161. Saghayam S, Chaguturu SK, Kumarasamy N, Solomon S, Mayer KH, Wanke C, et al. Lipoatrophy is the predominant presentation of HIV-associated lipodystrophy in southern India. Clin Infect Dis. 2004;38(11):1646-7.
162. Tsuda LC, Silva MM, Machado AA, Fernandes AP. Body changes: antiretroviral therapy and lipodystrophy syndrome in people living with HIV/ aids. Rev Lat Am Enfermagem. 2012;20(5):847-53.
163. Heath KV, Hogg RS, Singer J, Chan KJ, O'Shaughnessy MV, Montaner JS, et al. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based chort. J Acquir Immune Defic Syndr. 2002;30(4):440-7.
164. Joly V, Flandre P, Meiffredy V, Leturque N, Harel M, Aboulker JP, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS. 2002;16(18):2447-54.
165. Kampira E, Kumwenda J, Van Oosterhout JJ, Dandara C. Mitochondrial subhaplogroups and differential risk of stavudine-induced lipodystrophy in Malawian HIV/AIDS patients. Pharmacogenomics. 2013;14(16):1999-2004.
166. Spire B, Carrieri P, Sopha P, Protopopescu C, Prak N, Quillet C, et al. Adherence to antiretroviral therapy in patients enrolled in a comprehensive care program in Cambodia: a 24-month follow-up assessment. Antivir Ther. 2008;13(5):697-703.
167. Saghayam S, Kumarasamy N, Cecelia AJ, Solomon S, Mayer K, Wanke C, et al. Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based generic highly active antiretroviral therapy in South India. Clin Infect Dis. 2007;44(2):295-300.
168. Bussmann H, Wester CW, Thomas A, Novitsky V, Okezie R, Muzenda T, et al. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial. J Acquir Immune Defic Syndr. 2009;51(1):37-46.
169. Desclaux A, Boye S. Perceptions of lipodystrophy among PLHIV after 10 years of antiretroviral therapy in Senegal. Bull Soc Pathol Exot. 2014; 107(4):246-51.
170. Goedecke JH, Micklesfield LK, Levitt NS, Lambert EV, West S, Maartens G, et al. Effect of different antiretroviral drug regimens on body fat distribution of HIV-infected South African women. AIDS Res Hum Retroviruses. 2013; 29(3):557-63.
171. Sinxadi PZ, Dave JA, Samuels DC, Heckmann JM, Maartens G, Levitt NS, et al. Mitochondrial genomics and antiretroviral therapy-associated metabolic complications in HIV-infected Black South Africans: a pilot study. AIDS Res Hum Retroviruses. 2013;29(7):1031-9.
172. Zinn RJ, Serrurier C, Takuva S, Sanne I, Menezes CN. HIV-associated lipodystrophy in South Africa: the impact on the patient and the impact on the plastic surgeon. J Plast Reconstr Aesthet Surg. 2013;66(6):839-44.
173. Azzoni L, Crowther NJ, Firnhaber C, Foulkes AS, Yin X, Glencross D, et al. Association between HIV replication and serum leptin levels: an observational study of a cohort of HIV-1-infected South African women. J Int AIDS Soc. 2010;13:33. doi:10.1186/1758-2652-13-33.
174. Sathekge M, Maes A, Kgomo M, Stolz A, Ankrah A, Van de Wiele C, et al. Evaluation of glucose uptake by skeletal muscle tissue and subcutaneous fat in HIV-infected patients with and without lipodystrophy using FDG-PET. Nucl Med Commun. 2010;31(4):311-4.
175. Li T, Guo F, Li Y, Zhang C, Han Y, Lye W, et al. An antiretroviral regimen containing 6 months of stavudine followed by long-term zidovudine for first-line HIV therapy is optimal in resource-limited settings: a prospective, multicenter study in China. Chin Med J (Engl). 2014;127(1):59-65.
176. Signorini DJ, Oliveira Netto AM, Monteiro MC, Signorini DH, Codec¸o CT, Bastos FI, et al. Differences in body fat distribution assessed by ultrasonography in patients receiving antiretroviral drugs. Rev Assoc Med Bras. 2012; 58(2):197-203.
177. Anjos EM, Pfrimer K, Machado AA, Cunha SF, Salomão RG, Monteiro JP, et al. Nutritional and metabolic status of HIV-positive patients with lipodystrophy during one year of follow-up. Clinics (Sao Paulo). 2011;66(3):407-10.
178. Diehl LA, Fabris BA, Barbosa DS, De Faria EC, Wiechmann SL, Carrilho AJ. Metformin increases HDL3-cholesterol and decreases subcutaneous truncal fat in nondiabetic patients with HIV-associated lipodystrophy. AIDS Patient Care STDS. 2008;22(10):779-86.
179. Tungsiripat M, El-Bejjani D, Rizk N, Hu B, Ross AC, Walker UA, et al. Changes in inflammation, oxidative stress, mitochondrial DNA content after Rosiglitazone in HIV Lipoatrophy. J AIDS Clin Res. 2012;3(8):174.
180. de Larrañaga GF, Bocassi AR, Puga LM, Alonso BS, Benetucci JA. Endothelial markers and HIV infection in the era of highly active antiretroviral treatment. Thromb Res. 2003;110(2-3):93-8.
181. Arruda Júnior ER, Lacerda HR, Moura LC, Albuquerque MeF, Miranda Filho DeB, Diniz GT, et al. Profile of patients with hypertension included in a cohort with HIV/AIDS in the state of Pernambuco, Brazil. Arq Bras Cardiol. 2010;95(5):640-7.
182. Signorini DJ, Monteiro MC, Andrade MeF, Signorini DH, Eyer-Silva WeA. What should we know about metabolic syndrome and lipodystrophy in AIDS? Rev Assoc Med Bras. 2012;58(1):70-5.
183. Ceccato MG, Bonolo PF, Souza Neto AI, Araújo FS, Freitas MI. Antiretroviral therapy-associated dyslipidemia in patients from a reference center in Brazil. Braz J Med Biol Res. 2011;44(11):1177-83.
184. Gasparotto AS, Sprinz E, Lazzaretti RK, Kuhmmer R, Silveira JM, Basso RP, et al. Genetic polymorphisms in estrogen receptors and sexual dimorphism in fat redistribution in HIV-infected patients on HAART. AIDS. 2012;26(1): 19-26.
185. Castelar L, Silva MM, Castelli EC, Deghaide NH, Mendes-Junior CT, Machado AA, et al. Interleukin-18 and interferon-gamma polymorphisms in Brazilian human immunodeficiency virus-1-infected patients presenting with lipodystrophy syndrome. Tissue Antigens. 2010;76(2):126-30.
186. de Carvalho EH, Miranda Filho DeB, Ximenes RA, de Albuquerque MeF, de Melo HR, Gelenske T, et al. Prevalence of hyperapolipoprotein B and associations with other cardiovascular risk factors among human immunodeficiency virus-infected patients in Pernambuco, Brazil. Metab Syndr Relat Disord. 2010;8(5):403-10.
187. Guimarães MM, de Oliveira AR, Penido MG, Queiroz LC, Goulart EM, Greco DB, et al. Ultrasonographic measurement of intra-abdominal fat thickness in HIV-infected patients treated or not with antiretroviral drugs and its correlation to lipid and glycemic profiles. Ann Nutr Metab. 2007; 51(1):35-41.
188. Silva MM, Simões RT, Castelli EC, Mendes-Junior CT, Deghaide NH, Tsuda LC, et al. TNF microsatellite alleles may confer protection against the development of lipodystrophy syndrome in Brazilian HIV patients. Int J Immunogenet. 2010;37(5):379-85.
189. Ronchini KR, Duarte AJ, Casseb JS, Gidlund M. Cardiovascular complications and increased levels of circulating modified low density lipoprotein in HIV patients and patients with lipodystrophy. Braz J Med Biol Res. 2004;37(1): 119-22.
190. Vassimon HS, de Paula FJ, Machado AA, Monteiro JP, Jordão AA. Hypermetabolism and altered substrate oxidation in HIV-infected patients with lipodystrophy. Nutrition. 2012;28(9):912-6.
191. Justina LB, Luiz MC, Maurici R, Schuelter-Trevisol F. Prevalence and factors associated with lipodystrophy in AIDS patients. Rev Soc Bras Med Trop. 2014;47(1):30-7.
192. Menezes de Pádua CA, Moura CS. Availability of data on adverse reactions to antiretroviral drugs in medical charts according to the naranjo algorithm: an example of a Brazilian historical cohort. Clin Drug Investig. 2014;34(6): 395-402.